Using Tranexamic Acid to Reduce Bleeding During Upper GI Endoscopic Procedures
Comparison Between Epinephrine Versus Tranexamic Acid Usage During Upper Gastrointestinal Tract Endoscopic Resection Procedures for the Reduction of Intraprocedural and Postprocedural Bleeding
This study is testing if using tranexamic acid can help reduce bleeding during upper GI endoscopic procedures for patients with stomach and duodenal growths.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assaf-Harofeh Medical Center Government |
| Locations | 1 site (Be'er Ya'aqov) |
| Trial ID | NCT05688020 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of tranexamic acid (TXA) in preventing bleeding during endoscopic mucosal resection (EMR) of upper gastrointestinal lesions. The research focuses on patients undergoing procedures for gastric and duodenal neoplasms, where bleeding is a common complication. By administering TXA locally, the study aims to reduce both intraprocedural and postprocedural bleeding rates, potentially improving patient outcomes and reducing the need for additional interventions. The study is conducted at a tertiary academic center, ensuring a robust patient population and clinical oversight.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who are referred for endoscopic resection of non-neoplastic or neoplastic lesions in the upper gastrointestinal tract.
Not a fit: Patients with a history of allergic reactions to TXA, seizures, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of bleeding complications during upper GI endoscopic procedures, leading to better patient outcomes.
How similar studies have performed: While the use of TXA in other surgical contexts has shown promise, this specific application in upper GI endoscopic procedures is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients referred for endoscopic resection of a non-neoplastic and neoplastic lesions in the upper GI presenting to our tertiary academic center. * Age \> 18 years Exclusion Criteria: * patients with histories of allergic reactions to TXA * history of seizures * pregnancy
Where this trial is running
Be'er Ya'aqov
- Shamir Medical Center — Be'er Ya'aqov, Israel (Recruiting)
Study contacts
- Principal investigator: Anton Bermont, MD — Assaf-Harofeh Medical Center
- Study coordinator: Anton Bermont, MD
- Email: bermont@doctor.com
- Phone: 972-52-6944145
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.